LEXINGTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of cancers, today announced that Phase 1 data for CUDC-907, Curis' proprietary dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor will be presented at the 57th American Society of Hematology Annual Meeting to be held from Dec. 5-8, 2015 in Orlando, FL.
The Principal Investigator of the study, Dr. Anas Younes, Chief of the Lymphoma Service of the Memorial Sloan Kettering Cancer Center in New York City, will present the data in an oral presentation at the meeting.
Additional information on the presentation can be found below and abstracts can be accessed at www.hematology.org.
|Date/Session Time:||Sunday, Dec. 6, 2015, 12:00 PM – 1:30 PM|
|Session Name:||Lymphoma: Chemotherapy, excluding Pre-Clinical Models: NHL – New Drugs|
|Presentation Title:||Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma|
|Presentation Time:||1:00 PM|
|Location:||Orange County Convention Center, W311|
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, an oral dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of PD-L1/ VISTA and IRAK4. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
CONTACT: For More Information: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 firstname.lastname@example.org Media Contact David Schull Russo Partners (212) 845-4271 email@example.com